General Information of Drug (ID: DM4YFU5)

Drug Name
4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine Drug Info
Synonyms CHEMBL1080666
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44820377
TTD Drug ID
DM4YFU5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [2]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [4]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [5]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [7]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [8]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [9]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [10]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [10]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [11]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [11]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [11]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [11]
AZAKENPAULLONE DM61H07 Discovery agent N.A. Investigative [12]
Thieno analogue of kenpaullone DMIOTHG Discovery agent N.A. Investigative [12]
3,4-bis(indol-3-yl)maleimide derivative DMEQ1HC Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [1]
G2/mitotic-specific cyclin B1 (CCNB1) TT9P6OW CCNB1_HUMAN Inhibitor [1]

References

1 Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
2 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
5 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
6 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
7 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
8 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
9 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
10 Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
11 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
12 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.